Evidence that erythrocyte DARC-positive phenotype can affect the GVHD occurrence after HLA-identical sibling HSCT

Erythrocyte membrane antigen frequencies in patients with Type II congenital smell loss

“…The Fy b haplotype is overrepresented in patients suffering from graft-versus-host disease possibly due to more effective chemokine transcytosis and leukocyte recruitment mediated by that form of DARC [47]. Perhaps Fy b is better at maintaining certain critical proinflammatory cytokine moieties in nasal mucus than Fy a and smell loss associated with Type II congenitals is due in part to their lower incidence of Fy b expression.…”

From genetic single candidate gene studies to complex genomics of GvHD

“…Among other chemokine receptors, CCR9 and Duffy Antigen Receptor for Chemokine (DARC) have been previously studied (Inamoto et al , ; Sellami et al , ).…”

“…With respect to these observations and the results of Reshef et al (2012), testing the effect of the CCR5 antagonist maraviroc, it could be concluded that the genotyping for the CCR5delta32 polymorphism may aid in the further development of new GvHD therapeutic strategies involving usage of the CCR5 antagonist maraviroc as an effective drug for CCR5delta32 negative transplants to prevent aGvHD. Among other chemokine receptors, CCR9 and Duffy Antigen Receptor for Chemokine (DARC) have been previously studied (Inamoto et al, 2010;Sellami et al, 2011). (2015) TYMS (TS) 5 0 UTR 28 bp repeat 3R/2R genotype Increased risk for aGvHD Robien et al (2006) aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; D, donor; GvHD, graft-versus-host disease; HLA, human leucocyte antigen; R, recipient.…”

“…DARC is expressed on erythrocytes. Sellami et al () suggested that the donor DARC 146G allele and T(−46)G(146) haplotype, coding for the FY2 version of DARC, may act as a facilitator of chemokine transcytosis and, subsequently, leucocyte migration into GvHD target organs.…”